Compare Capital One Financial Corp. (COF) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Ginkgo Bioworks Holdings Inc — how do they compare? Capital One Financial Corp. trades at $206.2 (market cap $126.46B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Capital One Financial Corp. is far larger — about 214.1× Ginkgo Bioworks Holdings Inc's market cap, and Capital One Financial Corp. pays a 1.56% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| COF | DNA | |
|---|---|---|
Market Cap | $126.46B | $590.53M |
Sector | Financials | Health |
52-Week High | $257.94 | $16.14 |
52-Week Low | $176.10 | $5.48 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $203.02, up 0.74% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but strong revenue growth to $53.43B in 2025. Analyst consensus remains positive with a $252.40 price target and 62.5% buy ratings, while the Discover integration presents significant expansion opportunities amid credit risk concerns.
COF offers potential upside from current levels with Wall Street optimism around the Discover acquisition, though investors face headwinds from rising delinquencies and margin compression. The stock's valuation at 62.44 P/E appears elevated relative to modest ROE of 3.34%, requiring careful monitoring of integration execution and credit quality trends.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
